Sol-Gel Q2 Loss Beats Estimates; Phase 3 SGT-610 Data Due Late November
SLGL has more than doubled off its 52-week low of $15.538.
Summary
Sol-Gel reported Q2 2026 revenue of $0.6 million and a net loss of $3.7 million ($1.13 per share), beating the analyst consensus loss of $2.57 per share. The company's pivotal Phase 3 trial of SGT-610 for Gorlin syndrome is progressing well, with a dropout rate of only 9% (10 of 113 patients), considerably lower than expected. Last patient last visit is expected in September 2026, with top-line results scheduled for late November 2026. Sol-Gel also announced initiation of two new patidegib studies (high-frequency BCC and neo-adjuvant BCC surgery) and a provisional patent filing for an injectable HHi for odontogenic keratocysts. Cash of $49.3 million is expected to fund operations into Q1 2028. The positive trial retention data and upcoming Phase 3 readout are the key drivers for the stock.
At the time of this announcement, SLGL was trading at $78.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $256.9M. The 52-week trading range was $15.54 to $97.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.